Compare Smith & Nephew plc (SNN) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs US Bancorp — how do they compare? Smith & Nephew plc trades at $27.67 (market cap $11.63B), while US Bancorp trades at $62 (market cap $97.36B). The key difference: US Bancorp is far larger — about 8.4× Smith & Nephew plc's market cap, and US Bancorp pays the higher dividend (3.33%). Which is the better fit depends on your goals.
| SNN | USB | |
|---|---|---|
Market Cap | $11.63B | $97.36B |
Sector | Health | Financials |
52-Week High | $38.53 | $65.42 |
52-Week Low | $27.80 | $45.28 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
U.S. Bancorp (USB) trades at $62.49, down 1.39% today, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 12.47 and net income margin of 27.61%, supported by three consecutive quarterly EPS beats. Recent news highlights innovation in digital payments and business banking expansion. Cash flow trends indicate volatility, with 2025 net cash flow negative at -$9.61 billion.
The outlook is mixed: analyst consensus targets $70.27 (12.4% upside) with 50% buy ratings, but technicals suggest near-term pressure. Key risks include debt levels and macroeconomic sensitivity. Earnings growth and dividend stability ($0.52 quarterly) provide support, though investor sentiment is cautious amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
